The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Open accessAbstract
BACKGROUND: Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear factor-kappaB ligand (RANKL) that blocks its binding to RANK, inhibiting the development and activity of osteoclasts, decreasing bone resorption, and increasing bone density. Given its unique actions, denosumab may be useful in the treatment of osteoporosis. METHODS: We enrolled 7868 women between the ages of 60 and 90 years who had a bone mineral density T score of less than -2.5 but not less than -4.0 at the lumbar spine or total hip. Subjects were randomly assigned to receive either 60 mg of denosumab or placebo subcutaneously every 6 months for 36 months. The primary end point was new vertebral fracture. Secondary end points included nonvertebral and hip fractures. RESULTS: As compared with placebo, denosumab reduced the risk of new radiographic vertebral fracture, with a cumulative incidence of 2.3% in the denosumab group, versus 7.2% in the placebo group (risk ratio, 0.32; 95% confidence interval [CI], 0.26 to 0.41; P<0.001)--a relative decrease of 68%. Denosumab reduced the risk of hip fracture, with a cumulative incidence of 0.7% in the denosumab group, versus 1.2% in the placebo group (hazard ratio, 0.60; 95% CI, 0.37 to 0.97; P=0.04)--a relative decrease of 40%. Denosumab also reduced the risk of nonvertebral fracture, with a cumulative incidence of 6.5% in the denosumab group, versus 8.0% in the placebo group (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01)--a relative decrease of 20%. There was no increase in the risk of cancer, infection, cardiovascular disease, delayed fracture healing, or hypocalcemia, and there were no cases of osteonecrosis of the jaw and no adverse reactions to the injection of denosumab. CONCLUSIONS: Denosumab given subcutaneously twice yearly for 36 months was associated with a reduction in the risk of vertebral, nonvertebral, and hip fractures in women with osteoporosis. (ClinicalTrials.gov number, NCT00089791.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is true for fracture patients with BMD in both the low bone mass and osteoporosis range [49–58].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [56]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There are abundant data that patients with spine and hip fractures will have reduced fracture risk if treated with pharmacologic therapy.”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [56]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Denosumab reduces the incidence of vertebral fractures by about 68 %, hip fractures by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [56]
The cited source says what the claim attributes to it.
In the citing paper
“Denosumab reduces the incidence of vertebral fractures by about 68 %, hip fractures by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [56]
The cited source says what the claim attributes to it.
In the citing paper
“Denosumab reduces the incidence of vertebral fractures by about 68 %, hip fractures by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Statistical Analysis of Failure Time Data.
Aitkin, M. A., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,875
Hapeman, D. E., & Agresti, A. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,407
Agresti, A. (2002) · Wiley Series in Probability and Statistics · doi:10.1002/0471249688 · Cited by 6,746
Osteoclast differentiation and activation
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures
Johnell, O., & Kanis, J. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0172-4 · Cited by 4,770
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Self-citationBlack, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationEpidemiology and outcomes of osteoporotic fractures
Cummings, S. R., & Melton, L. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08657-9 · Cited by 3,821
Self-citationVertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Self-citation
Flagged first, then by citations
Research works printed but not linked: 2
- Wells G, 2008, Cochrane Database Syst Rev, 1, CD004523
- Martin TJ, 2004, J Musculoskelet Neuronal Interact, 4, 243
Cited by
Sorted by citations
Items 301–400 of 1,006
Boonen, S., Ferrari, S., Miller, P. D., Eriksen, E. F., Sambrook, P. N., Compston, J. E., Reid, I. R., Vanderschueren, D., & Cosman, F. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1570 · Cited by 114
Self-citationMcClung, M. R., Lewiecki, E. M., Geller, M. L., Bolognese, M. A., Peacock, M., Weinstein, R. L., Ding, B., Rockabrand, E., Wagman, R. B., & Miller, P. D. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2052-4 · Cited by 116
Self-citationDrug induced osteonecrosis of the jaw
Hamadeh, I. S., Ngwa, B. A., & Gong, Y. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.04.007 · Cited by 122
Lorentzon, M., Branco, J., Brandi, M. L., Bruyère, O., Chapurlat, R. D., Cooper, C. C., Cortet, B., Díez‐Pérez, A., Ferrari, S., Gáspárik, A. I., et al. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01063-9 · Cited by 121
The 2024 UK clinical guideline for the prevention and treatment of osteoporosis
Gregson, C. L., Armstrong, D., Avgerinou, C., Bowden, J., Cooper, C. C., Douglas, L., Edwards, J., Gittoes, N. J. L., Harvey, N. C., Kanis, J. A., et al. (2025) · Archives of Osteoporosis · doi:10.1007/s11657-025-01588-3 · Cited by 136
Grey, A. B., Bolland, M. J., Horne, A. M., Wattie, D. J., House, M. E., Gamble, G. D., & Reid, I. R. (2012) · Bone · doi:10.1016/j.bone.2012.03.016 · Cited by 114
Self-citationControl of bone formation by the serpentine receptor Frizzled-9
Albers, J., Schulze, J., Beil, F. T., Gebauer, M., Baranowsky, A., Keller, J., Marshall, R. P., Wintges, K., Friedrich, F. W., Priemel, M., et al. (2011) · The Journal of Cell Biology · doi:10.1083/jcb.201008012 · Cited by 116
Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy
Ahern, E. S., Smyth, M. J., Dougall, W. C., & Teng, M. W. L. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0095-y · Cited by 115
Ferrari, S., Libanati, C. R., Lin, C. J. F., Brown, J. P., Cosman, F., Czerwinski, E. J., de Gregorio, L. H., Malouf, J., Reginster, J.-Y., Wang, A., et al. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3722 · Cited by 116
Self-citationGlucocorticoid-induced Osteoporosis
Whittier, X., & Saag, K. G. (2015) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2015.08.005 · Cited by 116
Leder, B. Z., Tsai, J. N., Jiang, L. A., & Lee, H. (2017) · Bone · doi:10.1016/j.bone.2017.03.006 · Cited by 112
Osteoporosis in Older Persons: Old and New Players
Zanker, J., & Duque, G. (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15716 · Cited by 112
A myostatin and activin decoy receptor enhances bone formation in mice
Bialek, P., Parkington, J. D., Li, X., Gavin, D., Wallace, C. E., Zhang, J., Root, A. R., Yan, G., Warner, L., Seeherman, H. J., et al. (2013) · Bone · doi:10.1016/j.bone.2013.12.002 · Cited by 113
Bone Health in Adult Cancer Survivorship
Lustberg, M. B., Reinbolt, R. E., & Shapiro, C. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.2097 · Cited by 111
Díez‐Pérez, A., Marín, F., Eriksen, E. F., Kendler, D. L., Krege, J. H., & Delgado‐Rodríguez, M. (2018) · Bone · doi:10.1016/j.bone.2018.09.020 · Cited by 110
New Insights Into Osteoclast Biology
McDonald, M. M., Kim, A. S., Mulholland, B. S., & Rauner, M. (2021) · JBMR Plus · doi:10.1002/jbm4.10539 · Cited by 116
Overdiagnosis of bone fragility in the quest to prevent hip fracture
Järvinen, T. L. N., Michaëlsson, K., Jokihaara, J., Collins, P. G. S., Perry, T. L., Mintzes, B. J., Musini, V. M., Erviti, J., Gorricho, J., Wright, J. M., et al. (2015) · BMJ · doi:10.1136/bmj.h2088 · Cited by 114
Future directions of bone-targeted therapy for metastatic breast cancer
Onishi, T., Hayashi, N., Theriault, R. L., Hortobágyi, G. N., & Ueno, N. T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.134 · Cited by 110
Treatment of osteoporosis in men
Kaufman, J., Reginster, J.-Y., Boonen, S., Brandi, M. L., Cooper, C. C., Dere, W. H., Devogelaer, J.-P., Díez‐Pérez, A., Kanis, J. А., McCloskey, E. V., et al. (2012) · Bone · doi:10.1016/j.bone.2012.11.018 · Cited by 109
Regulation of bone homeostasis: signaling pathways and therapeutic targets
Wu, Z., Li, W., Jiang, K., Lin, Z., Qian, C., Wu, M., Xia, Y., Li, N., Zhang, H., Xiao, H.-X., et al. (2024) · MedComm · doi:10.1002/mco2.657 · Cited by 129
Saito, T., Sterbenz, J. M., Malay, S., Zhong, L., MacEachern, M., & Chung, K. C. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4175-0 · Cited by 111
Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis
Lyu, H., Yoshida, K., Zhao, S. S., Wei, J., Zeng, C., Tedeschi, S. K., Leder, B. Z., Lei, G., Tang, P., & Solomon, D. H. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0882 · Cited by 111
Recovery Versus Persistence of Disordered Mineral Metabolism in Kidney Transplant Recipients
Evenepoel, P. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2012.12.019 · Cited by 109
New Insights into Monogenic Causes of Osteoporosis
Mäkitie, R. E., Costantini, A., Kämpe, A., Alm, J. J., & Mäkitie, O. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00070 · Cited by 108
Lamy, O., Stoll, D., Aubry‐Rozier, B., & Rodríguez, E. G. (2019) · Current Osteoporosis Reports · doi:10.1007/s11914-019-00502-4 · Cited by 110
Genetics of osteoporosis: accelerating pace in gene identification and validation
Li, W., Hou, S.-X., Yu, B., Li, M., Férec, C., & Chen, J. (2009) · Human Genetics · doi:10.1007/s00439-009-0773-z · Cited by 108
First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI.
Semler, O., Netzer, C., Hoyer‐Kuhn, H., Becker, J., Eysel, P., & Schöenau, E. (2012) · PubMed · Cited by 107
Bonani, M., Frey, D., Brockmann, J. G., Fehr, T. H., Mueller, T., Saleh, L., von Eckardstein, A., Graf, N. M., & Wuthrich, R. P. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13692 · Cited by 106
McClung, M. R. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3553-3 · Cited by 106
Self-citationParathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy
Leder, B. Z. (2017) · Current Osteoporosis Reports · doi:10.1007/s11914-017-0353-4 · Cited by 105
Lyu, H., Jundi, B., Xu, C. Q., Tedeschi, S. K., Yoshida, K., Zhao, S. S., Nigwekar, S. U., Leder, B. Z., & Solomon, D. H. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02236 · Cited by 110
Everts‐Graber, J., Lehmann, D., Burkhard, J.-P., Schaller, B., Gahl, B., Häuselmann, H., Studer, U., Ziswiler, H., Reichenbach, S., & Lehmann, T. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4472 · Cited by 105
Wnt signaling and osteoporosis
Manolagas, S. C. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.04.013 · Cited by 104
Rubin, K. H., Rothmann, M. J., Holmberg, T., Høiberg, M., Möller, S., Barkmann, R., Glüer, C.-C., Hermann, A. P., Bech, M., Gram, J., et al. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4326-3 · Cited by 104
Reduction in the Risk of Clinical Fractures After a Single Dose of Zoledronic Acid 5 Milligrams
Reid, I. R., Black, D. M., Eastell, R., Bucci-Rechtweg, C. M., Su, G., Hue, T. F., Mesenbrink, P. G., Lyles, K. W., & Boonen, S. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2868 · Cited by 104
Self-citationBody, J. J., Bergmann, P., Boonen, S., Boutsen, Y., Devogelaer, J.-P., Goemaere, S., Kaufman, J., Rozenberg, S., & Reginster, J.-Y. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1223-4 · Cited by 105
Lentle, B. C., Berger, C., Probyn, L. J., Brown, J. P., Langsetmo, L., Fine, B., Lian, K., Shergill, A. K., Trollip, J., Jackson, S., et al. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3222 · Cited by 104
Rochette, L., Méloux, A., Rigal, E., Zeller, M., Cottin, Y., & Vergely, C. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.08.015 · Cited by 108
Wu, X., Li, F., Dang, L., Liang, C., Lü, A., & Zhang, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00076 · Cited by 103
RANKL Inhibitors Induce Osteonecrosis of the Jaw in Mice With Periapical Disease
Aghaloo, T. L., Cheong, S., Bezouglaia, O., Kostenuik, P. J., Atti, E., Dry, S., Pirih, F. Q. M., & Tetradis, S. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2097 · Cited by 103
Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab
Gatti, D., Viapiana, O., Fracassi, E., Idolazzi, L., Dartizio, C., Povino, M. R., Adami, S., & Rossini, M. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1681 · Cited by 102
Self-citationCellular senescence and the skeleton: pathophysiology and therapeutic implications
Khosla, S., Farr, J. N., & Monroe, D. G. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154888 · Cited by 106
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis
Russell, R. G. G. (2010) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s8054 · Cited by 102
Postmenopausal osteoporosis: Assessment and management
Rizzoli, R. (2018) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2018.09.005 · Cited by 107
Watts, N. B., Grbic, J. T., Binkley, N., Papapoulos, S. E., Butler, P. W., Yin, X., Tierney, A., Wagman, R. B., & McClung, M. R. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01965 · Cited by 104
Self-citationThe impact of bone marrow adipocytes on osteoblast and osteoclast differentiation
Muruganandan, S., & Sinal, C. J. (2014) · IUBMB Life · doi:10.1002/iub.1254 · Cited by 100
Safety of Long-Term Bisphosphonate Therapy for the Management of Osteoporosis
Lewiecki, E. M. (2011) · Drugs · doi:10.2165/11585470-000000000-00000 · Cited by 102
Kostenuik, P. J., Smith, S. Y., Jolette, J., Schroeder, J., Pyrah, I. T. G., & Ominsky, M. S. (2011) · Bone · doi:10.1016/j.bone.2011.03.769 · Cited by 99
Efficacy, effectiveness and side effects of medications used to prevent fractures
Reid, I. R. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12339 · Cited by 99
Self-citationGallacher, S., & Dixon, T. (2010) · Calcified Tissue International · doi:10.1007/s00223-010-9420-x · Cited by 98
RANKL, denosumab, and giant cell tumor of bone
Thomas, D. M. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328354c129 · Cited by 98
Guerrini, M. M., Okamoto, K., Komatsu, N., Sawa, S., Danks, L., Penninger, J. M., Nakashima, T., & Takayanagi, H. (2015) · Immunity · doi:10.1016/j.immuni.2015.10.017 · Cited by 100
Evenepoel, P., Claes, K. J., Meijers, B. K. I., Laurent, M. R., Bammens, B., Naesens, M., Sprangers, B., Pottel, H., Cavalier, E., & Kuypers, D. R. J. (2019) · Kidney International · doi:10.1016/j.kint.2018.12.024 · Cited by 98
The Treatment Gap in Osteoporosis
Ayub, N., Faraj, M., Ghatan, S., Reijers, J. A. A., Napoli, N., & Oei, L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10133002 · Cited by 102
Diagnosis and Management of Osteoporosis in Advanced Kidney Disease: A Review
Ginsberg, C., & Ix, J. H. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.06.031 · Cited by 98
The Role of Microbial Biofilms in Osteonecrosis of the Jaw Associated with Bisphosphonate Therapy
Kumar, S., Gorur, A., Schaudinn, C., Shuler, C. F., Costerton, J. W., & Sedghizadeh, P. P. (2010) · Current Osteoporosis Reports · doi:10.1007/s11914-010-0008-1 · Cited by 101
Bone targeting for the treatment of osteoporosis
Lühmann, T. C., Germershaus, O., Gröll, J., & Meinel, L. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.10.001 · Cited by 100
Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor
Zhang, C., Ibrahim, P. N., Zhang, J., Burton, E. A., Habets, G. G. M., Zhang, Y., Powell, B., West, B. L., Matusow, B., Tsang, G., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219457110 · Cited by 98
Ominsky, M. S., Stouch, B., Schroeder, J., Pyrah, I. T. G., Stolina, M., Smith, S. Y., & Kostenuik, P. J. (2011) · Bone · doi:10.1016/j.bone.2011.04.001 · Cited by 97
Dempster, D. W., Brown, J. P., Fahrleitner‐Pammer, A., Kendler, D. L., Rizzo, S., Valter, I., Wagman, R. B., Yin, X., Yue, S. V., & Boivin, G. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02669 · Cited by 97
Association Between Drug Treatments for Patients With Osteoporosis and Overall Mortality Rates
Cummings, S. R., Lui, L., Eastell, R., & Allen, I. E. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.2779 · Cited by 99
Self-citationSalmon Calcitonin Use and Associated Cancer Risk
Overman, R. A., Borse, M., & Gourlay, M. L. (2013) · Annals of Pharmacotherapy · doi:10.1177/1060028013509233 · Cited by 96
Anti-Osteoporotic Therapy After Fragility Fracture Lowers Rate of Subsequent Fracture
Bawa, H. S., Weick, J. W., & Dirschl, D. R. (2015) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.n.01275 · Cited by 97
Hopkins, R. B., Goeree, R. A., Pullenayegum, E., Adachi, J. D., Παπαϊωάννου, Α., Xie, F., & Thabane, L. (2011) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-12-209 · Cited by 95
Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates
Horne, A. M., Mihov, B., & Reid, I. R. (2018) · Calcified Tissue International · doi:10.1007/s00223-018-0404-6 · Cited by 95
Self-citationDrugs for the management of osteoporosis: a review.
Khajuria, D. K., Razdan, R., & Mahapatra, D. R. (2011) · PubMed · Cited by 95
Sardar, Z. M., Coury, J. R., Cerpa, M., DeWald, C. J., Ames, C. P., Shuhart, C., Watkins, C., Polly, D. W., Dirschl, D. R., Klineberg, E. O., et al. (2021) · Spine · doi:10.1097/brs.0000000000004268 · Cited by 95
Cellular and molecular mechanisms of alcohol-induced osteopenia
Luo, Z., Liu, Y., Liu, Y., Chen, H., Shi, S., & Liu, Y. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2585-y · Cited by 95
Screening, diagnosis and treatment of osteoporosis: a brief review
Bernabei, R. (2014) · Clinical cases in mineral and bone metabolism · doi:10.11138/ccmbm/2014.11.3.201 · Cited by 94
Raterman, H. G., & Lems, W. F. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00714-4 · Cited by 96
Effects of Zoledronate on Cancer, Cardiac Events, and Mortality in Osteopenic Older Women
Reid, I. R., Horne, A. M., Mihov, B., Stewart, A., Garratt, E., Bastin, S., & Gamble, G. D. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3860 · Cited by 93
Self-citationLangdahl, B. L. (2020) · Bone · doi:10.1016/j.bone.2020.115516 · Cited by 95
Glucocorticoid-Induced Osteoporosis: Why Kids Are Different
Ward, L. M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00576 · Cited by 96
Management of osteoporosis of the oldest old
Rizzoli, R., Branco, J., Brandi, M. L., Boonen, S., Bruyère, O., Cacoub, P., Cooper, C. C., Díez‐Pérez, A., Duder, J., Fielding, R. A., et al. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2755-9 · Cited by 94
Management of chronic pain in osteoporosis: challenges and solutions
Paolucci, T., Saraceni, V. M., & Piccinini, G. (2016) · Journal of Pain Research · doi:10.2147/jpr.s83574 · Cited by 93
Denosumab-related osteonecrosis of the jaw
Dios, P. D., López-Cedrún, J. L., Arenaz, J., & Scully, C. M. (2012) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2012.0323 · Cited by 92
Broadwell, A., Chines, A. A., Ebeling, P. R., Franek, E., Huang, S., Smith, S., Kendler, D. L., Messina, O. D., & Miller, P. D. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa851 · Cited by 92
Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab
Anastasilakis, A. D. (2012) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s24239 · Cited by 93
Kalisch, L. M., Caughey, G. E., Roughead, E. E., & Gilbert, A. L. (2011) · Australian Prescriber · doi:10.18773/austprescr.2011.084 · Cited by 93
Suen, P. K., & Qin, L. (2015) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2015.08.004 · Cited by 111
The Roles of RANK/RANKL/OPG in Cardiac, Skeletal, and Smooth Muscles in Health and Disease
Marcadet, L., Bouredji, Z., Argaw, A., & Frenette, J. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.903657 · Cited by 99
Ye, C., Ebeling, P. R., & Kline, G. A. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01385-6 · Cited by 99
Hadji, P., Παπαϊωάννου, Ν., Gielen, E., Tepie, M. F., Zhang, E., Frieling, I., Geusens, P., Makras, P., Resch, H., Möller, G., et al. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3164-4 · Cited by 93
Cathepsin K Inhibition: A New Mechanism for the Treatment of Osteoporosis
Duong, L. T., LEUNG, A. T., & Langdahl, B. L. (2015) · Calcified Tissue International · doi:10.1007/s00223-015-0051-0 · Cited by 90
Individualizing osteoporosis therapy
Silverman, S. L., & Christiansen, C. (2012) · Osteoporosis International · doi:10.1007/s00198-011-1775-y · Cited by 90
Self-citationPrevention and rehabilitation of osteoporosis
Kerschan‐Schindl, K. (2016) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-015-0417-y · Cited by 90
Brazilian guidelines for the diagnosis and treatment of postmenopausal osteoporosis
Radominski, S., Bernardo, W. M., de Paula, A. P., Albergaria, B., Moreira, C., Fernandes, C. E., Castro, C. H. D. M., Zerbini, C. A. F., Domiciano, D. S., de Mendonça, L. M. C., et al. (2017) · Revista Brasileira de Reumatologia (English Edition) · doi:10.1016/j.rbre.2017.07.001 · Cited by 111
Zhou, W., Liu, Y., Shen, J., Yu, B., Bai, J., Lin, J., Guo, X., Sun, H., Chen, Z., Yang, H., et al. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/4019619 · Cited by 90
Hsu, S.-H., Chen, L.-R., & Chen, K.-H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212139 · Cited by 105
Ebeling, P. R., Daly, R. M., Kerr, D. A., & Kimlin, M. G. (2013) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2013.tb04225.x · Cited by 89
Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy
Leder, B. Z. (2018) · JBMR Plus · doi:10.1002/jbm4.10041 · Cited by 90
The underlying pathophysiology and therapeutic approaches for osteoporosis
Awasthi, H., Mani, D., Singh, D. R., & Gupta, A. K. (2018) · Medicinal Research Reviews · doi:10.1002/med.21504 · Cited by 90
Severe Hypocalcemia Following Denosumab Injection in a Hemodialysis Patient
McCormick, B. B., Davis, J. L., & Burns, K. D. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.06.019 · Cited by 89
Arthritogenic alphaviruses: new insights into arthritis and bone pathology
Chen, W., Foo, S., Sims, N. A., Herrero, L. J., Walsh, N. C., & Mahalingam, S. (2014) · Trends in Microbiology · doi:10.1016/j.tim.2014.09.005 · Cited by 95
Recent advances in the pathogenesis and treatment of osteoporosis
Curtis, E. M., Moon, R. J., Dennison, E. M., Harvey, N. C., & Cooper, C. C. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-4-360 · Cited by 89
Alami, S., Hervouet, L., Poiraudeau, S., Briot, K., & Roux, C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158365 · Cited by 91
Nuclear Receptors in Bone Physiology and Diseases
Imai, Y., Youn, M., Inoue, K., Takada, I., Kouzmenko, A., & Kato, S. (2013) · Physiological Reviews · doi:10.1152/physrev.00008.2012 · Cited by 95
Anastasilakis, A. D., Yavropoulou, M. P., Makras, P., Sakellariou, G. T., Papadopoulou, F. G., Gerou, S., & Papapoulos, S. E. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-1027 · Cited by 88
Recent Progresses in the Treatment of Osteoporosis
Li, S., He, S., Xie, P.-Y., Li, W., Zhang, X., Li, T.-F., & Li, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.717065 · Cited by 91
Genant, H. K., Engelke, K., Hanley, D. A., Brown, J. P., Omizo, M., Bone, H. G., Kivitz, A., Fuerst, T. P., Wang, H., Austin, M., et al. (2010) · Bone · doi:10.1016/j.bone.2010.04.594 · Cited by 89
Self-citation
Metadata
- Authors
- Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., Kutilek, S., Adami, S., Zanchetta, J., Libanati, C., Siddhanti, S., & Christiansen, C.
- Affiliations
- University of California, San Francisco (US)
- Columbia University Irving Medical Center (US)
- University of Sheffield (GB)
- University of Auckland (NZ)
- Inserm (FR)
- Amgen (United States) (US)
- University of Verona (IT)
- Center for Clinical & Basic Research (DK)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-08-20
- Volume
- 361
- Issue
- 8
- Pages
- 756-765
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2160005424
- Cited by
- 3,489
- References
- 39
- Citations by year
- 2026: 187 · 2025: 220 · 2024: 203 · 2023: 164 · 2022: 226 · 2021: 210 · 2020: 223 · 2019: 200 · 2018: 208 · 2017: 195 · 2016: 180 · 2015: 238 · 2014: 168 · 2013: 222 · 2012: 197
- FWCI
- 223.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BORIS (University Library Bern) (submittedVersion)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- IRIS (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lithuanian University of Health Sciences (submittedVersion)
- ResearchSpace (University of Auckland) (submittedVersion, cc-by)
- SERVAL (Université de Lausanne) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Servier
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- denosumab, osteoporosis, postmenopausal women, fracture prevention, RANKL inhibition, vertebral fractures, hip fracture, non-vertebral fractures, bone mineral density, monoclonal antibodies, osteoclasts, bone resorption, adverse events, osteonecrosis of the jaw, hypocalcemia, cancer risk, cardiovascular risk
- MeSH terms
- Denosumab, Aged, Aged, 80 and over, Antibodies, Monoclonal, Female, Hip Fractures, Humans, Middle Aged, Risk, Bone Density, Osteoporosis, Postmenopausal, Incidence, Spinal Fractures, Bone Remodeling, Bone Density Conservation Agents, Fractures, Bone, RANK Ligand, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
